What is Spect?
Spect operates at the vanguard of medical technology, specializing in the early detection of eye diseases through an AI-enabled telemedicine platform. By positioning the eye as a diagnostic window into systemic health, the company provides a unique value proposition: the ability to identify indicators of whole-body conditions, such as stroke, through non-invasive screening. The platform is designed to streamline clinical workflows by training medical assistants and generating diagnostic reports in minutes rather than days. This efficiency not only improves patient outcomes but also enhances the financial viability of clinics adopting their technology. Spect's core competencies lie in its sophisticated data-science architecture, which transforms complex ocular imagery into actionable clinical insights, effectively democratizing access to high-quality diagnostic care.
How much funding has Spect raised?
Spect has raised a total of $3.6M across 2 funding rounds:
Debt
$107K
Angel/Seed
$3.5M
Debt (2021): $107K with participation from PPP
Angel/Seed (2021): $3.5M led by 10x, Morado Ventures, XTX Ventures, and AME Cloud
Key Investors in Spect
Morado Ventures
Morado Ventures is a tech-forward seed fund that invests in exceptional founders developing transformative companies. The firm focuses on early-stage, data-driven companies addressing complex technological challenges across various sectors, including AI, industrial IoT, robotics, and health tech.
10x
10x is a venture capital firm focused on supporting early-stage startups with high-growth potential through strategic mentorship and capital allocation.
XTX Ventures
XTX Ventures is the venture capital arm of XTX Markets, focusing on strategic investments in innovative technology companies that demonstrate significant potential for market disruption.
What's next for Spect?
With the recent capital secured, Spect is well-positioned to scale its operations and deepen its integration within the healthcare ecosystem. The strategic focus will likely shift toward expanding the reach of its AI-enabled diagnostic tools and refining its predictive algorithms for broader systemic disease detection. As the company matures, it will likely prioritize partnerships with large-scale healthcare providers to solidify its market position. The ongoing investment in its telemedicine infrastructure will be critical for maintaining its competitive edge in the rapidly evolving health-tech landscape, ensuring that Spect remains a leader in delivering best-in-class diagnostic services to a global patient base.
See full Spect company page
